MORTALIDAD DE PACIENTES HOSPITALIZADOS POR COVID-19 EN MÉXICO, REVISIÓN SISTEMÁTICA: MORTALITY OF PATIENTS HOSPITALIZED BY COVID-19 IN MEXICO, SYSTEMATIC REVIEW

Ana  Portocarrerero Granados; Lya A Castro Rodriguez; Antonio  Sandoval-Cabrera; María del Socorro Romero Figueroa

doi:10.25176/RFMH.v23i4.5877

Authors

Ana Portocarrerero Granados Facultad de Medicina, Coordinación de Investigación, Campus Universitario Siglo XXI, Zinacantepec México
Lya A Castro Rodriguez Facultad de Medicina, Coordinación de Investigación, Campus Universitario Siglo XXI, Zinacantepec México
Antonio Sandoval-Cabrera Investigador, Hospital para el niño del Instituto Materno Infantil del Estado de México
María del Socorro Romero Figueroa Facultad de Medicina, Coordinación de Investigación, Campus Universitario Siglo XXI, Zinacantepec México; Investigador Asociado de la Universidad Anáhuac México, Centro de Investigación en Ciencias de la Salud Lomas Anáhuac 786, Huixquilucan, México

DOI:

https://doi.org/10.25176/RFMH.v23i4.5877

Keywords:

COVID 19, diabetes, hypertension, Mexico, mortality, obesity

Abstract

Introduction

Since the start of the pandemic, Mexico was one of the countries with the highest mortality rates from COVID 19.

Objective

To determine if type 2 diabetes mellitus, arterial hypertension, and obesity increase mortality in patients diagnosed with COVID-19 who required hospitalization in Mexico.

Method

Systematic review in Pubmed MeSH, Web of Science, Lilas, Scielo, and Google Schoolar with the terms MESH COVID-19, SARS-COV2, Coronavirus, and Mexico for the years 2020 and 2021, in English or Spanish. Two reviewers selected the studies, two additional reviewers participated in the analysis of the studies.

Results

Seventy three studies carried out in Mexico from 2020 to 2021 were included with information obtained from the databases of the National Epidemiological Surveillance System of Mexico. With an average age of 52.9 ± 13.27 years, 64% of the included patients were women, the most prevalent pathology was obesity with 24.23% (IQR 17.74-22.28 = 22%), followed by hypertension. arterial 22.23% (IQR 17.98-23.44 = 22%) and finally Diabetes mellitus with 18.10% (interquartile range 9.39 -14.61 = 22%). In general, a mortality rate of 16.76 (IQR 9-39-14.61) was reported. 71% of the studies (52) did not report specific mortality related to comorbidities.

conclusions

The most common comorbidity among patients hospitalized for COVID in Mexico was obesity, followed by type 2 diabetes mellitus and hypertension.

Downloads

Download data is not yet available.

References

World Health Organization. Archived: WHO Timeline - COVID-19 [Internet]. Wold Health Organization. 2020 [citado el 11 de junio de 2023]. p. 2020. Disponible en: https://www.who.int/news/item/27-04-2020-who-timeline---covid-19

Noyola DE, Hermosillo-Arredondo N, Ramírez-Juárez C, Werge-Sánchez A. Association between obesity and diabetes prevalence and COVID-19 mortality in Mexico: an ecological study. J Infect Dev Ctries. 2021;15(10):1396–403. doi: 10.3855/JIDC.15075

Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759–65. doi: 10.15585/MMWR.MM6924E2

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. doi: 10.1016/S0140-6736(20)30566-3

Gobierno de México. Exceso de mortalidad en México COVID-19 [Internet]. 21 de junio. 2021 [citado el 11 de junio de 2023]. Disponible en: https://coronavirus.gob.mx/exceso-de-mortalidad-en-mexico/

INEGI. Prevalencia de Obesidad, Hipertensión y Diabetes para los Municipios de México 2018. 2020.

Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75(11):2829–45. doi: 10.1111/ALL.14429

Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. J Virol. 2005;79(23):14614–21. doi: 10.1128/jvi.79.23.14614-14621.2005

Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002;532(1–2):107–10. doi: 10.1016/S0014-5793(02)03640-2

Verma A, Xu K, Du T, Zhu P, Liang Z, Liao S, et al. Expression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice. Mol Ther Methods Clin Dev. 2019;14:161–70. doi: 10.1016/J.OMTM.2019.06.007

Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res [Internet]. 2020 [citado el 12 de junio de 2023];157. doi: 10.1016/J.PHRS.2020.104833

López-Otero D, López-Pais J, Cacho-Antonio CE, Antúnez-Muiños PJ, González-Ferrero T, Pérez-Poza M, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry. Rev Esp Cardiol. 2021;74(2):175–82. doi: 10.1016/j.recesp.2020.05.030

Carvajal C. El endotelio: estructura, función y disfunción endotelial. Medicina Legal de Costa Rica. 2017;34(2):90–100.

Xu S wen, Ilyas I, Weng J ping. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2022;44(4):695–709. doi: 10.1038/s41401-022-00998-0

Faraj SS, Jalal PJ. IL1β, IL-6, and TNF-α cytokines cooperate to modulate a complicated medical condition among COVID-19 patients: case-control study. Ann Med Surg (Lond). 2023;85(6):2291–7. doi: 10.1097/MS9.0000000000000679

Chernyak B V., Popova EN, Prikhodko AS, Grebenchikov OA, Zinovkina LA, Zinovkin RA. COVID-19 and Oxidative Stress. Biochemistry (Mosc). 2020;85(12):1543. doi: 10.1134/S0006297920120068

Barquera S, Rivera JA. Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies. Lancet Diabetes Endocrinol. 2020;8(9):746–7. doi: 10.1016/S2213-8587(20)30269-2

Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA, Gaona- Pineda EB, Lazcano-Ponce E, Martínez-Barnetche J, Alpuche-Arana C R-DJ. Encuesta Nacional de Salud y Nutrición 2020 sobre Covid-19 [Internet]. Cuernavaca, México; 2021. Disponible en: https://www.insp.mx/resources/images/stories/2023/docs/230811_Ensanut2020sobreCovid_Nacionales.pdf

Dafallah Albashir AA. The potential impacts of obesity on COVID-19. Clin Med (Lond). 2020;20(4):E109–13. doi: 10.7861/CLINMED.2020-0239

Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851. doi: 10.5114/AOMS.2016.58928

Ni YN, Luo J, Yu H, Wang YW, Hu YH, Liu D, et al. Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis. Crit Care. 2017;21(1). doi: 10.1186/S13054-017-1615-3

Jayarangaiah A, Kariyanna PT, Chen X, Jayarangaiah A, Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response. Clin Appl Thromb Hemost. 2020;26. doi: 10.1177/1076029620943293

Pettit NN, MacKenzie EL, Ridgway JP, Pursell K, Ash D, Patel B, et al. Obesity is Associated with Increased Risk for Mortality Among Hospitalized Patients with COVID‐19. Obesity (Silver Spring) [Internet]. 2020 [citado el 27 de junio de 2023];28(10):1806. doi: 10.1002/OBY.22941

Kuperberg SJ, Navetta-Modrov B. The Role of Obesity in the Immunopathogenesis of COVID-19 Respiratory Disease and Critical Illness. Am J Respir Cell Mol Biol. 2021;65(1):113–21. doi: 10.1165/RCMB.2020-0236TR/SUPPL_FILE/DISCLOSURES.PDF

Biscarini S, Colaneri M, Ludovisi S, Seminari E, Pieri TC, Valsecchi P, et al. The obesity paradox: Analysis from the SMAtteo COvid-19 REgistry (SMACORE) cohort. Nutrition, Metabolism, and Cardiovascular Diseases [Internet]. 2020 [citado el 27 de junio de 2023];30(11):1920. doi: 10.1016/J.NUMECD.2020.07.047

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi: 10.1016/J.DIABRES.2009.10.007

INEGI. Comunicado de prensa 538/19. Características de las defunciones registradas. 2019;1–65.

Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2020;14(4):535–45. doi: 10.1016/j.dsx.2020.04.044

Alegre-Díaz J, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, et al. Diabetes and Cause-Specific Mortality in Mexico City. New England Journal of Medicine [Internet]. 2016 [citado el 27 de junio de 2023];375(20):1961–71. doi: 10.1056/NEJMOA1605368/SUPPL_FILE/NEJMOA1605368_DISCLOSURES.PDF

Bradley SA, Banach M, Alvarado N, Smokovski I, Bhaskar SMM. Prevalence and impact of diabetes in hospitalized COVID-19 patients: A systematic review and meta-analysis. J Diabetes [Internet]. 2022 [citado el 13 de agosto de 2023];14(2):144–57. doi: 10.1111/1753-0407.13243

Juárez-Ramírez C, Reyes-Morales H, Gutiérrez-Alba G, Reartes-Peñafiel DL, Flores-Hernández S, Muños-Hernández JA, et al. Local health systems resilience in managing the COVID-19 pandemic: lessons from Mexico. Health Policy Plan [Internet]. 2022 [citado el 16 de septiembre de 2023];37(10):1278–94. doi: 10.1093/HEAPOL/CZAC055

Juárez-Ramírez C, Théodore FL, Gómez-Dantés H. Vulnerability and risk: reflections on the COVID-19 pandemic. Rev Esc Enferm. 2022; doi: 10.1590/S1980-220X2020045203777.Vulnerability

Villafuerte-García A. La detección del SARS-CoV-2: un elemento crítico para el control de la pandemia. Facultad de Medicina UNAM. 2022;3(27):8–12.

Parra-Bracamonte GM, Lopez-Villalobos N, Velazquez MA, Parra-Bracamonte FE, Perales-Torres AL, Juárez Rendón KJ. Comparative analysis of risk factors for COVID-19 mortality before, during and after the vaccination programme in Mexico. Public Health. 2023;215:94–9. doi: 10.1016/J.PUHE.2022.12.006